The first patient in the Phase 1B clinical trial was dosed at the Sarah Cannon Transplant &
Cellular Therapy Program at St. David’s South Austin Medical Center in Austin, Texas. The
patient received CHM 1101 therapy as second line therapy.
So they're moving to earlier initiations?
Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $12.43M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $2.004K | 500.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 70005872 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 88923724 | 24 |
View Market Depth
| Last trade - 09.59am 28/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |